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Abstract
Background and Aims: Acute hepatitis C infection usually ends in chronic infection, while in a minority of patients it is
spontaneously cleared. The current population-based study is performed on a large cohort in Golestan province of Iran to
examine the demographic correlates of Spontaneous Hepatitis C Clearance.
Methods: Serum samples used in this study had been stored in biorepository of Golestan Cohort Study. These samples were
evaluated for anti hepatitis C Virus by third generation Enzyme-linked immunosorbent assay (ELISA). Subjects who tested
positive were then invited and tested by Recombinant Immunoblot Assay (RIBA) and Ribonucleic Acid Polymerase Chain
Reaction test (PCR). If tested positive for RIBA, subjects were recalled and the two tests were re-done after 6 months. Those
subjects who again tested positive for RIBA but negative for PCR were marked as cases of spontaneous clearance.
Results: 49,338 serum samples were evaluated. The prevalence of Chronic Hepatitis C Virus (CHCV) infection based on PCR
results was 0.31%. Among those who had acquired hepatitis C, the rate of SC was 38%. In multivariate analysis, illicit drug
use both Injecting Use (OR=3.271, 95% CI: 1.784–6.000, p-value,0.001) and Non-Injecting Use (OR=1.901, 95% CI: 1.068–
3.386, p-value=0.029) were significant correlates of CHCV infection versus SC.
Conclusions: Illicit drug use whether intravenous or non-intravenous is the only significant correlate of CHCV, for which
several underlying mechanisms can be postulated including repeated contacts with hepatitis C antigen.
Citation: Poustchi H, Esmaili S, Mohamadkhani A, Nikmahzar A, Pourshams A, et al. (2011) The Impact of Illicit Drug Use on Spontaneous Hepatitis C Clearance:
Experience from a Large Cohort Population Study. PLoS ONE 6(8): e23830. doi:10.1371/journal.pone.0023830
Editor: Paul Proost, University of Leuven, Rega Institute, Belgium
Received February 25, 2011; Accepted July 26, 2011; Published August 24, 2011
Copyright:  2011 Poustchi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by Tehran University of Medical Sciences. The study was not supported by any other internal or external resources. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: malek@ams.ac.ir
Introduction
Hepatitis C virus (HCV) infection is an important global health
problem with estimates of 170 million HCV-infected individuals
worldwide [1,2]. Prevalence of hepatitis C all around the world
ranges from 0.02% to18% [3]. In Iran, several studies have been
performed on seroprevalence of HCV. Based on a comprehensive
systematic review by Alavian et al. [4], the prevalence of HCV
infection among the general population in 6 out of 30 provinces of
Iran is 0.16%. Also the estimated seroprevalence of HCV in a
more recent population-based study by Merat et al. [5] is around
0.5%, which is concordant with previous studies on blood donors
(0.08%–1.3%) [6,7].
In majority of patients exposed to HCV, the disease becomes
chronic, but in a proportion of cases ranging from 14% to 45% the
virus is spontaneously cleared from the body and the Ribonucleic Acid
Polymerase Chain Reaction test (PCR) test becomes negative [8–15].
Several factors have been proposed as correlates of HCV
persistence, including viral and demographic factors, and also
route of disease transmission. [8–11,14–19].
Among demographic factors, male gender [19–23], older age
[14,23], and ethnic background [12,21,24] are suggested as
correlates for HCV persistence. Host genetic variation is also
assumed to explain the heterogeneity in HCV persistence across
individuals because such differences occur even if individuals are
exposed to the same HCV strain [18,25,26].
Certain high risk behaviors also increase the risk of HCV
persistence, namely illicit drug use (both Injecting and non-
Injecting) [21,27], alcohol consumption [12,14], and unprotected
sexual behaviors that lead to co-infection with Human Immuno-
deficiency Virus (HIV) and Hepatitis B Virus (HBV) [14,28–30].
Still, there are major controversies on the role of these risk factors
in various studies.
Along with effective prevention of HBV by universal vaccina-
tion in developing countries including Iran, HCV is becoming a
more important public health concern replacing HBV [31–33].
There are quite a few studies that report the high rate of HCV co-
infection with HBV, HIV, and venereal diseases such as syphilis in
Iran [34,35] especially among prisoners [36], which needs
immediate attention. Appropriate policy-making in this regard
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23830necessitates accurate estimation of HCV burden. Distinguishing
patients who spontaneously clear HCV from those who develop
progressive liver disease and their risk factors is crucial for decision
making.
In the current study, we have determined the rate of HCV
spontaneous clearance (SC) and its demographic and host
correlates in a large prospective population-based study in Iran.
Results
All subjects whose serum had tested positive for third generation
Enzyme-linked immunosorbent assay (ELISA) were recruited for
baseline examination and were recalled after 6 months and no
subject was missed in the prospective phase of the study. Three
hundred and eighty one (381) subjects tested positive for ELISA,
among them, 247 subjects were also positive for Recombinant
Immunoblot Assay (RIBA), therefore 134 subjects were labeled as
false positive. Chronic HCV infection (CHCV) was confirmed in
152 subjects by PCR and the 95 cases with negative PCR was
labeled as SC. During repeat serological testing after 6 months all
CHCV subjects remained positive and in none of SC cases did the
result of the test change. The HCV seroprevalence in Golestan
cohort was 0.5% based on the result of RIBA, and 0.31% based on
the result of PCR and 38.5% of infected subjects had
spontaneously cleared the infection.
There was no significant difference in the mean age between the
4 groups (CHCV, SC, false positives, and HCV negatives). The
frequency of males was significantly higher among subjects with
CHCV infection (73.7%) and cases of SC (52.6%) than false
positives (47.0%) and HCV negatives (40.0%) (p,0.001).
The correlates of HCV acquisition in univariate and multivar-
iate logistic regression were sought. The ultimate correlates in
multivariate analysis were: history of blood transfusion, history of
imprisonment, family history of hepatitis, cigarette smoking, Non-
Injecting Drug Use (Non-IDU), and Injecting Drug Use (IDU)
(table 1).
The correlates of HCV persistence versus SC were sought.
Results of the univariate logistic regression are demonstrated in
table 2. Among significant correlates, body piercing appears to be
inversely associated with HCV persistence.
In the next step, correlates of HCV persistence versus SC were
sought using multiple logistic regression. The only variables that
remained in the model were IDU (OR=3.271, 95% CI: 1.784–
6.000, p-value,0.001) and Non-IDU (OR=1.901, 95% CI:
Table 1. Correlates of HCV acquisition in multivariate
analysis.
Factor OR 95% CI P-Value
History of blood transfusion No 1
Yes 2.65 1.27–5.55 0.010
History of imprisonment No 1
Yes 2.01 1.02–3.96 0.043
Family history of hepatitis No 1
Yes 3.65 1.27–10.43 0.016
Cigarette smoking No 1
Yes 2.33 1.25–4.36 0.008
Non-IDU No 1
Yes 2.09 1.16–3.78 0.015
IDU No 1
Yes 6.92 4.00–11.97 ,0.001
Abbreviations: Non-IDU: Non Injecting Drug Use; IDU: Injecting Drug Use.
doi:10.1371/journal.pone.0023830.t001
Table 2. Correlates of HCV persistence versus spontaneous
clearance in univariate analysis.
Factor OR 95% CI P-value
Gender Female 1
Male 2.52 1.47–4.33 ,0.001
Age for each 10 years 0.81 0.61–1.08 0.154
Marital status single 1
married 3.33 2.12–3.57 0.002
Ethnicity Non-
Turkman
1
Turkman 0.68 0.39–1.19 0.184
History of blood transfusion No 1
Yes 4.18 1.81–9.67 ,0.001
History of hospitalization No 1
Yes 1.23 0.74–2.05 0.432
History of surgery No 1
Yes 0.88 0.52–1.49 0.630
History of dentistry No 1
Yes 1.57 0.84–2.92 0.158
History of accident No 1
Yes 1.67 0.84–3.30 0.143
War injury No 1
Yes 2.49 0.80–7.74 0.115
History of imprisonment No 1
Yes 3.70 1.82–7.14 ,0.001
History of tattoing No 1
Yes 1.70 0.44–6.59 0.440
History of traditional phlebotomyNo 1
Yes 1.87 0.71–4.92 0.206
History of body piercing No 1
Yes 0.46 0.27–0.78 0.004
Family history of hepatitis No 1
Yes 2.075 1.10–3.91 0.024
Cigarette smoking No 1
Yes 2.048 1.19–3.52 0.009
Traditional tobacco smoking No 1
Yes 2.137 1.09–4.18 0.027
Non-IDU No 1
Yes 2.418 1.42–4.13 0.001
Alcohol consumption No 1
Yes 3.061 1.21–7.74 0.018
Body Mass Index 1.00 0.95–1.05 0.997
IDU No 1
Yes 14.26 7.80–26.07 ,0.001
The test was performed on all 247 patients who had a true positive ELISA test
(cases of chronic HCV infection plus cases of spontaneous clearance).
Abbreviations: Non-IDU: Non Injecting Drug Use; IDU: Injecting Drug Use.
doi:10.1371/journal.pone.0023830.t002
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correlates and confounders.
Discussion
To the best of our knowledge, the current study is the first that
has been conducted in such a large scale on HCV spontaneous
clearance in Iran. In this study we were able to demonstrate that
38.5% of HCV infected subject might clear HCV infection
spontaneously which is in agreement with many previous studies
[8–10,12–14,37]. Also we found that both IDU and non-IDU are
the main correlates of CHVC that significantly decrease the
chance of SC among those patients who have acquired HCV
infection.
Over 50% of the total estimated 170 million HCV cases in the
world occur among illicit drug users and over 75% of incident
infections occur in this population [3]. It is known that, illicit drug
use is the major correlate of HCV persistence [21,23,37]. Several
hypotheses have been suggested to explain the underlying
mechanisms of this finding which mainly include: inefficient
immunological response [38] which is due to HIV in co-infected
subjects [12,14,39] other co-infection or co-morbidities [40,41],
and finally repeated -infection [27].
As for IDU, frequent monitoring of HCV infection status
among those who clear a primary infection demonstrated that re-
infection of HCV following control of a primary infection is
common [42], with detection of one or more subsequent infections
in almost 50% of cleared subjects [43]. In a study by Aitken and
colleagues, re-infection was documented in 46% of previously
cleared IDUs [44]. This data suggests that prior clearance of HCV
infection may not provide immunity against re-infection. However
it is of interest to know that the rate of self limited infection in
subjects who previously cleared the virus is higher than subjects
who do not clear the virus after initial infection [43,45].
Furthermore, maximum viral load and also duration of viremia
in re-infected cases are lower compared to the primary infection
[43].
Our results are in discordance with findings of Lewis-Ximenez
et al. [46], who found no relationship between illicit drug use or
age and rates of SC. The only correlate of CHCV infection
reported by them was low HCV antibody values [46]. The
insignificant results in this study may have been due to the small
sample size. Similarly, Santantonio et al. [47] found no
demographic factors as correlates of HCV persistence. The
possible explanation is that IDUs in Italy may be less likely to
reuse syringes for drug injection.
Our results on the role of Non-IDU in HCV persistence are in
accord with previous studies [21,27,48], but there are no agreed
upon mechanism for this finding. Some studies imply that nasal
inhalation or oral exposure may be plausible routes of transmission
probably through shared intranasal canola contaminated with
blood [48].
In our study, the seroprevalence of HCV based on RIBA is
0.5%, which is similar to that reported by Merat et al. [5];
however, the seroprevalence of HCV in our results based on PCR
is 0.31% which is again similar to that reported by Alavian et al.
[4]. The risk factors that correlate with HCV acquisition in our
study (table 1) are also similar to many previous reports.
In the current study, the rate of SC is significantly higher among
females versus males. Also in the univariate logistic regression,
male gender is a significant predictor of HCV persistence, and this
is supported by previous data [21,22,49]. Some previous studies
have reported that the rate of SC is higher among females. The
apparently higher rate of HCV SC in females is postulated to be
due to effect of sex hormone [50] or attributed to genetic and
immunological differences between males and females. In our
study, gender was not found to be a significant correlate of HCV
persistence in multivariate logistic regression analysis. The main
reason for this finding may be the fact that IDU is more common
among males. This finding implies that the inherent attributes of
female gender have probably no direct effect on the natural history
of CHCV which is discordant with previous studies
[20,22,25,49,51]. With a similar justification, the seemingly
protective role of body piercing in HCV persistence is due to
the fact that in our study, women added up to 95.4% of subjects
who had pierced while the percentage declined to 1.3% among
those who had not, which shows that body piercing is associated
with gender and thus is a confounder.
Since the Golestan Cohort Study (GCS) is an aged cohort and
the median age of our subjects was 54 years, re-infection might
have happened several times and seroconversion might have
happened at unknown time; therefore, our cohort may represent a
selection of subjects who have recovered from multiple bouts of
HCV infections. Studies in older HCV infected subjects
documented that prior clearance of HCV decreases the rate of
persistent re-infection compared to initial infection [29,45];
therefore, the duration of re-infection in subjects who have cleared
multiple infections may be progressively shorter with each re-
infection and this may have been the case in our study too but
longer follow up is required to document this claim.
Lastly we compared the rate of SC in Turkmens versus non-
Turkmens and in Turkmens versus immigrants from the southern
province of Sistan and Balouchestan, who are the second major
ethnic group residing in Golestan. Contrary to other studies, we
did not find significant difference in the rate of SC between
different ethnic groups residing in the province of Golestan.
[12,21,24].
The main strengths of our study are the prospective population-
based design and the large sample size which have been tested.
The main limitation is the absence of young subjects in study
population. Other limitation includes absence of HCV genotype
data.
In conclusion this study revealed a 38.5% spontaneous
clearance rate among HCV infected subjects in Golestan. We
were able to demonstrate that illicit drug use, either Injecting or
non-Injecting, are the main correlates of HCV persistence in
Golestan province. Harm reduction interventions including
distribution of sterile syringes among IDUs, can be an effective
Table 3. The demographic characteristics of GCS subjects
(N=49,338) whose serum were available for HCV testing.
Variable Number (%)
Gender Female 28,397 (57.6)
Male 20,941 (42.4)
Age 40–45 years 14,061 (28.5)
46–55 years 19,735 (40.0)
.55 years 15,542 (31.5)
Place of Residence Urban 9,868 (20.0)
Rural 39,470 (80.0)
Ethinicty Turkmen 36,707 (74.4)
Non-Turkmen 12,631 (25.6)
Abbreviations: GCS: Golestan Cohort Study; HCV: Hepatitis C Virus.
doi:10.1371/journal.pone.0023830.t003
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population, which may play an important role in reducing the
burden of HCV infection in Iran. Further studies which include
younger age populations are necessary in future.
Materials and Methods
The study was approved by the ethics committee of Digestive
Disease Research Center, Tehran University of Medical Sciences.
Written informed consent was obtained from all participants. To
determine the rate of HCV SC, we used serum samples stored in
biorepository of GCS. The details of GCS have been reported
elsewhere [52]. In short, GCS was originally designed to
investigate the burden and etiology of upper gastro-intestinal
cancers in Northeast of Iran. A total of 50,045 subjects aged 40–75
have been recruited from 3 main districts of the Golestan province
in southeast of the Caspian Sea and have been followed-up for 7
years. Subjects have been selected by multi-stage systematic cluster
random sampling. Tissue samples including blood, hair, and nail
have been collected and stored. The demographic characteristics
of the GCS subjects are demonstrated in table 3.
For the purpose of the current study, stored serum samples of
49,338 subjects were available for HCV study by ELISA (Diapro,
Italy). Positive subjects were contacted via telephone and invited to
refer for fresh blood sample collection. Invited subjects who did not
respond or were not able to come but did consent to participate in
study were visited at home and their blood sample was taken. Samples
were transferred in +4uC temperature which took less than 4 hours
from collection site to 280uC freezers. No subject was missed.
The newly collected fresh blood samples were tested by ELISA
again. All ELISA positive subjects were then tested by Recombinant
Immunoblot Assay (RIBA) (MT Company, Germany). RIBA negative
subjects were labeled as False Positives. RIBA positive subjects were
further tested by Ribonucleic Acid Polymerase Chain Reaction (PCR)
(STRPTM Hepatitis C Virus Detection Kit from Cinna Gen- Iran).
To test blood samples by PCR, an unthawed sample was used for
QubasTaqman with detection limit of 50 copy number.
Six months later, we again performed both RIBA and PCR on
subjects who had tested positive for RIBA in the first session. RIBA
and PCR positive subjects were classified as cases of chronic HCV
infection and RIBA positive but PCR negative subjects were
labeled as cases of SC. Control subjects were randomly selected
from the bio-repository of the whole cohort (Figure 1).
Demographic data for all subjects were extracted from the GCS
database. Data on history of exposure were similarly extracted
from the database for HCV negatives. All HCV positive subjects
were questioned again about risk factors at the time blood sample
was collected.
All analyses were carried out using the statistical software
package SPSS for Windows version 18 (Chicago: SPSS Inc., USA).
Continuous variables are summarized as mean 6 standard
deviation of the mean (SD) and categorical variables as frequency
and percentage unless otherwise stated. Logistic regression models
were used to investigate correlates of HCV acquisition and HCV
persistence. The selected multivariate model was backward Wald
in which, variables that were significant in univariate model were
included. P-values less than 0.05 were considered statistically
significant.
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